Stay updated on CDX-0159 in Chronic Urticaria: Clinical Trial
Sign up to get notified when there's something new on the CDX-0159 in Chronic Urticaria: Clinical Trial page.

Latest updates to the CDX-0159 in Chronic Urticaria: Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page now displays the completed Phase 2 study record for barzolvolimab in chronic spontaneous urticaria, including its design, eligibility criteria, study locations, and outcome measures.SummaryDifference75%

- Check8 days agoChange DetectedThe page remains a 403 Forbidden error page. Its footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check15 days agoChange DetectedA site-wide banner announces NIH website transition updates and says the term “Super Intelligence” is replacing “Artificial Intelligence” across some NIH content.SummaryDifference1%

- Check22 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2; the study page remains unavailable with a 403 error.SummaryDifference0.2%

- Check29 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study details with an error screen and a Home link. This indicates restricted access rather than an update to the study information.SummaryDifference18%

Stay in the know with updates to CDX-0159 in Chronic Urticaria: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CDX-0159 in Chronic Urticaria: Clinical Trial page.